BIOCRYST PHARMACEUTICALS ENTER AGREEMENT WITH GREEN CROSS TO DEVELOP AND COMMERICALIZE PERAMIVIR

A A

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced an agreement with Green Cross Corporation, South Korea for the development and commercialization in Korea of peramivir, BioCryst's potent influenza neuraminidase inhibitor.

StreetInsider.com (http://www.streetinsider.com/news.php?id=963334&st=p)